Skip to main content

Progyny, Inc. (PGNY)

New York Stock Exchange Healthcare Medical - Healthcare Information ServicesView data quality →
61.7Fair

ValueMarkers Composite Index

Top 84%#7,106 of 44,707
Undervalued

31% below intrinsic value ($24)

UndervaluedFair ValueOvervalued
Piotroski
5/9
Neutral
Beneish
-2.03
Investigate
Altman
6.60
Safe
DCF Value
$24
Undervalued
ROIC
9.6%
Adequate
P/E
24.7
Fair
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Progyny, Inc. (PGNY) — VMCI valuation read

Progyny, Inc. sits at VMCI 62/100, with the Healthcare sector median at 50. That 12-point spread is the first thing to note on PGNY: it tells the reader the composite is favorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on PGNY are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on PGNY: PGNY trades at 16.0x earnings, 11% below the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 16.0% sits 6.0pp above the Healthcare median (10.0%). The Risk read: net debt to EBITDA of 1.4x leaves covenant headroom, anchoring the bear scenario on a measurable balance-sheet metric.

PGNY rose 0.1% over the trailing 7 days, with a -6.8% read on a 30-day basis.

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

CEO: Peter Anevski675 employeesUSwww.progyny.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in PGNY’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.